Enfortumab vedotin

• Antibody-drug conjugate targeting Nectin-4 that is present on the surface of most urothelial cancer cells
• Indicated for urothelial cancer
• Common adverse effects include: rashes (about 50%, can be severe), alopecia (in about 50%); abdominal pain, anorexia, constipation, diarrhea, and nausea/vomiting; fatigue; myelosuppression; myalgias; dysgeusia; peripheral neuropathy (in about 50%, can be severe); dry eyes
  • Also liver enzyme abnormalities, insomnia, hyperglycemia
  • Rarely SJS/TEN and pneumonitis (median time to onset 3 months)